Details for Patent: 8,557,852

Which drugs does patent 8,557,852 protect, and when does it expire?

Patent 8,557,852 protects BEVYXXA and is included in one NDA.

This patent has thirty-one patent family members in twenty countries.

Summary for Patent: 8,557,852

Title:	Methods of using crystalline forms of a salt of a factor Xa inhibitor
Abstract:	The present invention provides methods for preventing or treating a condition characterized by undesired thrombosis in a mammal using a crystalline polymorph form of a maleate salt of a compound of Formula I that has activity against mammalian factor Xa. ##STR00001##
Inventor(s):	Grant; Craig (Burwell, GB), Kanter; James P. (San Ramon, CA), Langlands; Graeme (Soham, GB)
Assignee:	Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	12/550,291
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,557,852

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Portola Pharms Inc	BEVYXXA	betrixaban	CAPSULE;ORAL	208383-001	Jun 23, 2017		DISCN	Yes	No						PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
Portola Pharms Inc	BEVYXXA	betrixaban	CAPSULE;ORAL	208383-001	Jun 23, 2017		DISCN	Yes	No						PROPHYLAXIS OF VENOUS THROMBOSIS
Portola Pharms Inc	BEVYXXA	betrixaban	CAPSULE;ORAL	208383-002	Jun 23, 2017		DISCN	Yes	No						PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
Portola Pharms Inc	BEVYXXA	betrixaban	CAPSULE;ORAL	208383-002	Jun 23, 2017		DISCN	Yes	No						PROPHYLAXIS OF VENOUS THROMBOSIS

International Family Members for US Patent 8,557,852

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	056787
Argentina	106960
Austria	E549317
Australia	2006311544